After stopping Prolia (denosumab), you need to transition to a bisphosphonate medication to protect the bone density you gained during treatment. Without follow-up therapy, bone loss accelerates rapidly, and the risk of vertebral fractures increases three to five times within 6 to 18 months of your last injection. This rebound effect is well documented, and no major guideline recommends stopping Prolia without a plan for what comes next.
Why You Can’t Just Stop Prolia
Prolia works by blocking the cells that break down bone. When you stop, those cells come roaring back, often more aggressively than before treatment. This “rebound” effect is most intense in the first year after discontinuation. Without follow-up medication, roughly 8 to 10% of patients develop new vertebral fractures, typically within 10 months of their last dose.
The risk is highest for people who were on Prolia for more than three years. In data from the major clinical trials, patients who stopped after long-term use (beyond three years) had a multiple vertebral fracture rate of 11.3%, compared to 3.8% for those who used it short-term. Each additional year on Prolia roughly tripled the odds of multiple fractures after stopping. People who already had a fracture before or during treatment, and those who had never taken a bisphosphonate before starting Prolia, also face higher risk.
The Main Transition Medications
Bisphosphonates are the primary class of medication used after Prolia. Unlike Prolia, bisphosphonates bind directly to bone and stay there, providing a more durable effect that doesn’t reverse quickly when you stop taking them. Two options have the strongest evidence.
Zoledronic Acid (IV Infusion)
A single intravenous infusion of zoledronic acid, given approximately six months after your last Prolia injection, is the most widely recommended approach. For people who were on Prolia for less than about three years, one infusion is often enough to preserve most of the bone density gained. For those on longer-term treatment, the picture is more complicated. A single dose may only preserve about half of the gains, so a second infusion six months later is sometimes needed. Your doctor can check blood markers to decide whether a repeat dose is warranted.
Alendronate (Oral Tablet)
If an IV infusion isn’t practical or preferred, oral alendronate taken for at least one year is the main alternative. European guidelines suggest oral bisphosphonates for 12 to 24 months as a substitute for zoledronic acid. Alendronate appears effective at maintaining bone density after short-term Prolia use, though the evidence is somewhat less robust than for zoledronic acid, particularly after longer treatment courses.
Other Bisphosphonates
Risedronate is sometimes used, but studies show it results in greater bone loss compared to zoledronic acid. Ibandronate may be an option for people who can’t tolerate oral bisphosphonates due to stomach problems. Both are considered second-line choices.
Medications That Don’t Work for This
Not every osteoporosis drug can substitute here. Raloxifene does not appear to prevent the rebound spike in bone breakdown. Teriparatide, a bone-building injectable, actually led to decreases in bone density when used alone after Prolia in clinical studies, so it’s not recommended as a solo transition therapy. Romosozumab shows some early promise but lacks enough data to be a standard recommendation.
Timing Matters
The transition should not be delayed beyond six months after your last Prolia injection. Prolia is given every six months, so the medication from your final dose begins wearing off right around that mark. Most guidelines recommend starting the bisphosphonate at the six-month point, though the Endocrine Society has suggested eight months in some cases.
Your doctor will likely monitor blood markers that reflect how actively your body is breaking down bone. The key marker, called CTX, should ideally stay below 280 ng/L after the transition. Some newer research suggests an even lower target of 212 ng/L better predicts whether bone loss is truly controlled. If your levels rise above these thresholds, a repeat dose of zoledronic acid or continued oral therapy may be needed.
How Long the Follow-Up Treatment Lasts
The minimum recommended course of oral bisphosphonate therapy is one year, though 12 to 24 months is often suggested for people at higher fracture risk or those who were on Prolia for a long time. With zoledronic acid, the approach is more flexible: some patients need only a single infusion, while others require two doses spaced about six months apart. Bone density scans and blood marker checks help determine when it’s safe to stop.
People who gained the most bone density on Prolia paradoxically face the most rebound risk, because they have the most to lose. Your doctor should document your peak bone density on Prolia before planning withdrawal, since this helps gauge how aggressively the transition needs to be managed.
Calcium and Vitamin D During the Transition
Throughout the transition period, you should continue taking 1,000 mg of calcium and at least 400 IU of vitamin D daily. These are the same baseline amounts recommended during Prolia treatment itself. They don’t replace the need for a bisphosphonate but support the bone-preserving process. Many doctors recommend higher vitamin D doses (often 800 to 2,000 IU) depending on your blood levels, so it’s worth having yours checked.
What the Transition Looks Like in Practice
A typical sequence after your final Prolia injection goes something like this: you receive your last dose as scheduled, then around month six, you either get a zoledronic acid infusion (a 15-minute IV drip, usually done in an office or infusion center) or start taking a weekly alendronate pill. Around months 6 and 12, your doctor orders blood work to check bone turnover markers. A bone density scan is usually repeated about a year after stopping Prolia to confirm the transition is holding.
If markers stay low and bone density is stable, the bisphosphonate can often be stopped after one to two years. If markers spike or density drops significantly, additional treatment is added. The goal is not necessarily to maintain every fraction of bone density gained on Prolia, but to prevent the dangerous rapid loss that leads to fractures.